98%
921
2 minutes
20
Background: In multiple sclerosis, lower urinary tract symptoms are frequently observed depending on the site of involvement. A comprehensive assessment of these symptoms is crucial for their effective management.
Objective: This research was designed to evaluate the validity and reliability of the Turkish adaptation of the Core Lower Urinary Tract Symptom Scale (CLSS) in patients with multiple sclerosis (PwMS).
Methods: 71 PwMS who had an Expanded Disability Status Scale score of 6.5 or below was included. Data collection involved demographic information as well as responses to the CLSS, Overactive Bladder Questionnaire, Interstitial Cystitis Symptom Index, Interstitial Cystitis Problem Index, and International Prostate Symptom Score. To evaluate test-retest reliability, the CLSS was administered again under identical conditions after a 7-day interval.
Results: The internal consistency of the questionnaire was assessed, resulting in a Cronbach's alpha coefficient of 0.79. Test-retest reliability for the CLSS sub-items ranged from 0.593 to 0.950. No statistically significant differences were found between the sub-items scores of the test and retest administrations. (p > 0.05). Moreover, the subscales showed significant correlations with the other questionnaires, with correlation coefficients varying between 0.109 and 0.770. Straining, feeling incomplete emptying, and pain in the bladder sub-items did not show a significant correlation with the corresponding sub-items of other questionnaires (r = 0.109, 0.270, and 0.195, respectively).
Conclusion: The Turkish adaptation of the CLSS questionnaire has been proven to be a reliable and valid instrument for evaluating lower urinary tract symptoms in PwMS.
Clinicaltrials: Gov Number: NCT06599866.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s13760-025-02769-0 | DOI Listing |
Eur Heart J Open
September 2025
Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, Japan.
Aims: Intravenous tolvaptan sodium phosphate (IV-tolvaptan) is a novel aquaretic agent for acute decompensated heart failure (ADHF). This study evaluated its short-term effects and prognostic implications in clinical practice.
Methods And Results: In this retrospective cohort of 169 consecutive ADHF patients receiving IV-tolvaptan for the first time (mean age 76.
Exp Clin Transplant
August 2025
>From the Department of Urology, University Hospital Hradec Kralove, Hradec Kralove, Czechia; and the Charles University, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czechia.
Objectives: Kidney transplant is a life-saving procedure for patients with end-stage renal disease. Success of kidney transplant is highly dependent on maintaining the integrity of the endothelium and its protective layer, the endothelial glycocalyx. Ischemia-reperfusion injury, a common challenge in kidney transplant, can disrupt the endothelial glycocalyx, leading to various post-transplant complications.
View Article and Find Full Text PDFBMC Infect Dis
September 2025
Department of Laboratory Medicine, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, China.
Background: Serratia marcescens is an opportunistic pathogen increasingly associated with healthcare-associated infections and rising antimicrobial resistance. The emergence of multidrug-resistant (MDR) and carbapenem-resistant S. marcescens (CRSM) presents significant therapeutic challenges.
View Article and Find Full Text PDFAnaesthesiologie
September 2025
Klinik für Anästhesiologie, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität, Moorenstr. 5, 40225, Düsseldorf, Deutschland.
Sodium-glucose Cotransporter 2 (SGLT-2) inhibitors are oral antidiabetic drugs that were developed for the treatment of patients with diabetes mellitus and are now also approved for treating chronic heart failure and chronic kidney disease. By inhibiting SGLT‑2 in the proximal renal tubule, urinary excretion of glucose is increased. Large randomized trials have demonstrated improved glycemic control, reduced cardiovascular events and lower mortality but also an increased risk of urogenital infections and dehydration.
View Article and Find Full Text PDFWomen Health
September 2025
Nezahat Keleşoğlu Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Necmettin Erbakan University, Konya, Turkey.
This study compared the pelvic floor dysfunction (PFD) symptoms, knowledge level and quality of life inwomen with systemic sclerosis (SSc) and healthy. The study included 30 SSc and 30 healthy women. The presence and severity of PFD symptoms were evaluated using the Pelvic Floor Distress Inventory-20 (PFDI-20) (Subscales: Pelvic Organ Prolapse Distress Inventory-6 (POPDI-6), Colorectal-Anal Distress Inventory-8 (CRADI-8), and Urinary Distress Inventory-6 (UDI-6)).
View Article and Find Full Text PDF